News & Press Releases Swedish

Scandinavian ChemoTech AB publicerar delårsrapport för januari – mars 2024

Scandinavian ChemoTech AB (publ) publicerar härmed delårsrapport för Q1 2024. Rapporten finns bifogad till detta pressmeddelande och kan även hämtas från Bolagets hemsida (https://www.chemotech.se/investor-relations/financial-reports/) Perioden 1 januari - 31 mars 2024 · Nettoomsättningen uppgick till 1 345 KSEK (54) · Resultat före skatt uppgick till -3 203 KSEK (-5 034) · Resultat per aktie uppgick…

Read more

Scandinavian ChemoTech meddelar att QM & RA Direktör Eva Ståhl Wernersson lämnar företaget

Efter tre år som QA/RA chef i Scandinavian ChemoTechs ledningsgrupp väljer nu Eva Ståhl Wernersson att lämna sitt konsultuppdrag i Bolaget och gå vidare mot nya utmaningar. Eva Ståhl Wernersson har varit en viktig del av ChemoTech, under vilka hon har gjort betydande insatser för företagets följsamhet mot regelverket och kvalitetssäkringsåtgärder. Hon ledde bland annat…

Read more

Scandinavian ChemoTech publicerar 2023 års årsredovisning

Scandinavian ChemoTech meddelar att årsredovisningen för 2023 nu finns tillgänglig på bolagets hemsida: https://www.chemotech.se/investor-relations/financial-reports/. Årsredovisningen bifogas även till detta pressmeddelande.

Read more

News & Press Releases English

Scandinavian ChemoTech announces departure of QM & RA Director Eva Ståhl Wernersson

After three years as QA/RA manager in Scandinavian ChemoTech's management team, Eva Ståhl Wernersson now chooses to leave her consulting role in the Company and move on to new challenges. Eva Ståhl Wernersson has played a crucial role at ChemoTech, demonstrating considerable dedication to ensuring the company's compliance with regulations and quality assurance standards. One…

Read more

ChemoTech obtain approval of the third and last patent application in India

Scandinavian ChemoTech AB today announces that it has been granted its third and last patent application by The Patent Office, Government of India. The approved patent application pertains to the utilization of TSE for pain alleviation. The Patent Office, Government of India has approved the third and final patent application. This approval allows for the…

Read more

ChemoTech attains progress by obtaining patent protection for two essential patents in India

Scandinavian ChemoTech AB today announces that it has been granted two significant patent approvals by The Patent Office, Government of India. This implies that there won't be a requirement to engage in public tenders; rather, a simplified procurement process will be in place. The Patent Office, Government of India has approved two of the Company's…

Read more

ChemoTech Videos

2023

Invest Live | Emissionsaktuella AcuCort & ChemoTech presenterar med Q&A (Swedish)

Redeye Investor Forum - Company Presentation

Clinical strategy update from Medical Director Dr. Suhail Mufti

Redeye Fight Cancer Day 2023 - ChemoTech

2022

ChemoTech 2022 - Mohan Frick CEO summarises the year (Swedish)

ChemoTech Q2 2022 - Livestream Presentation (in Swedish)

SWECARE at EXPO 2020 DUBAI: "Closing Ceremony"

A conversation with Småbolagspodden

(Audio in Swedish)

I det senaste avsnittet av Småbolagspodden berättar Scandinavian ChemoTechs vd Mohan Frick om hur bolagets unika metod för cancerbehandling, via så kallad tumörspecifik elektroporation, ska hjälpa människor och djur världen över.

Lyssna på hela avsnittet här:
52. ChemoTech – Vill vara en kraft för skonsammare cancervård

2021

Presentation of Q3 - Analysera med oss November 2021 (Swedish)

ChemoTech presents for its upcoming Annual General meeting 24 May 2021. Spoken language is Swedish but the presentation is in English.

Innovative TSE technology increases the local effect of chemotherapy (Swedish)

ChemoTech answers questions from the shareholders; Part 1 (Swedish)

CEO Mohan Frick presenting at Erik Penser Bank Bolagsdag (Swedish)

Erik Penser Bank interview with CEO Mohan Frick (Swedish) 8 January 2021

Videos from 2020

Company Presentation of the Q3 report (Swedish) 11th of November 2020

Company Presentation (Swedish) 27th of October 2020

Videos from 2019

Share Day in Gothenburg, November 4 2019 (Swedish)

Videos from 2018

Share analysis ChemoTech Q2 2018 (Swedish)

Share Day in Malmö on May 22, 2018 (Swedish)

Our foundation

Our profound knowledge in electroporation forms the starting point for the company’s existing product and R&D projects: The IQwave™ specially designed for our TSE™ – Tumour Specific Electroporation technology which treats a range of various tumours.

Our research focus

Our aim is to document the effects of elctrochemotherapy for pain management for cancer patients, an area with significant unmet medical need.